

Eisai divests rights of select products in Asia to DKSH

07 November 2022 | News

Divesting rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH



Japanese firm Eisai Co. has entered into an agreement to divest its rights for muscle relaxant Myonal (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) in Asia (9 countries/regions) to a subsidiary of DKSH Holding.

The 9 countries/regions include Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines (Myonal only), Singapore, Taiwan (Merislon only), Thailand

In Asia and Latin America Pharmaceuticals Business (ALA Region), the company is shifting to a product portfolio centered on new global products in its strategic areas of neurology and oncology. Eisai believes that this divestiture agreement will accelerate the pursuit of the best marketing mix in the ALA Region.

Under the terms of the agreement, Eisai will receive a contractual up-front payment, and also plan to supply the products. Eisai will retain its manufacturing rights to and continue to distribute the products in countries such as Japan, China and South Korea.

DKSH is a leading provider of "Market Expansion Services" that comprehensively supports companies' business growth and entry into new markets, especially in Asia, and is already responsible for supplying Eisai's products in some parts of Asia.

The agreement will enable Eisai to strategically reallocate resources to other mid-to-long-term business growth areas so as to continue to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families.